Publisher Correction: Engineering and physical sciences in oncology: challenges and opportunities.
Nat Rev Cancer. 2018;18(11):720 - PMID: 30337715 - PMCID: PMC6357229 - DOI: 10.1038/s41568-018-0072-x
Inducible Nitric Oxide Synthase and CD11b+Gr1+ Cells Impair Lymphatic Contraction of Tumor-Draining Lymphatic Vessels.
Lymphat Res Biol. 2019;17(3):294-300 - PMID: 30358484 - PMCID: PMC6589499 - DOI: 10.1089/lrb.2018.0013
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Proc Natl Acad Sci U S A. 2019;116(6):2210-2219 - PMID: 30659155 - PMCID: PMC6369817 - DOI: 10.1073/pnas.1818357116
Mapping physical tumor microenvironment and drug delivery.
Clin Cancer Res. 2019;25(7):2024-2026 - PMID: 30630829 - PMCID: PMC6445672 - DOI: 10.1158/1078-0432.CCR-18-3724
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Nat Protoc. 2019;14(2):541-555 - PMID: 30617350 - PMCID: PMC6571021 - DOI: 10.1038/s41596-018-0105-7
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.
Nat Cell Biol. 2019;21(2):190-202 - PMID: 30598531 - PMCID: PMC6525097 - DOI: 10.1038/s41556-018-0256-3
Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study.
Transl Cancer Res. 2018;7(Suppl 1):S16-S20 - PMID: 30175050 - PMCID: PMC6117158 - DOI: 10.21037/tcr.2017.12.17
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Proc Natl Acad Sci U S A. 2019;116(10):4558-4566 - PMID: 30700545 - PMCID: PMC6410779 - DOI: 10.1073/pnas.1815515116
Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.
Proc Natl Acad Sci U S A. 2019;116(7):2662-2671 - PMID: 30700544 - PMCID: PMC6377457 - DOI: 10.1073/pnas.1818322116
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges.
Annu Rev Physiol. 2019;81:505-534 - PMID: 30742782 - PMCID: PMC6571025 - DOI: 10.1146/annurev-physiol-020518-114700
Retraction Note: A homing system targets therapeutic T cells to brain cancer.
The Impact of Taxane-based Chemotherapy on the Lymphatic System.
Ann Plast Surg. 2019;82(4S Suppl 3):S173-S178 - PMID: 30855384 - DOI: 10.1097/SAP.0000000000001884
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium.
Nat Biomed Eng. 2019;3(3):230-245 - PMID: 30948807 - PMCID: PMC6452896 - DOI: 10.1038/s41551-018-0334-7
Silence of the Lymphs: Some anaesthetic regimens inhibit lymphatic pumping.
Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy.
Proc Natl Acad Sci U S A. 2019;116(22):10674-10680 - PMID: 31040208 - PMCID: PMC6561160 - DOI: 10.1073/pnas.1819889116
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?
Cancer Res. 2019;79(9):2104-2106 - PMID: 31043429 - PMCID: PMC6601607 - DOI: 10.1158/0008-5472.CAN-19-0749
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Am Soc Clin Oncol Educ Book. 2019;39:165-174 - PMID: 31099649 - PMCID: PMC6596289 - DOI: 10.1200/EDBK_237987
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
JAMA Oncol. 2019;5(7):1020-1027 - PMID: 31145418 - PMCID: PMC6547247 - DOI: 10.1001/jamaoncol.2019.0892
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
The cancer cell glycocalyx proteoglycan glypican-1 mediates interstitial flow mechanotransduction to enhance cell migration and metastasis.
Biorheology. 2019;56(2-3):151-161 - PMID: 31256115 - DOI: 10.3233/BIR-180203
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol.
Endosc Ultrasound. 2019;8(4):235-240 - PMID: 31249159 - PMCID: PMC6714481 - DOI: 10.4103/eus.eus_16_19
The effects of valve leaflet mechanics on lymphatic pumping assessed using numerical simulations.
Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy.
Clin Transl Radiat Oncol. 2019;18:113-119 - PMID: 31341986 - PMCID: PMC6630151 - DOI: 10.1016/j.ctro.2019.04.013
Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC.
Vascular regulation of antitumor immunity.
cGMP-dependent protein kinase I in vascular smooth muscle cells improves ischemic stroke outcome in mice.
J Cereb Blood Flow Metab. 2019;39(12):2379-2391 - PMID: 31423931 - PMCID: PMC6893979 - DOI: 10.1177/0271678X19870583
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
JAMA Oncol. 2019;5(11):1566-1573 - PMID: 31465088 - PMCID: PMC6865228 - DOI: 10.1001/jamaoncol.2019.2294
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Breast Cancer Res Treat. 2020;179(1):113-123 - PMID: 31541381 - DOI: 10.1007/s10549-019-05445-z
Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res. 2020;26(1):206-212 - PMID: 31558474 - PMCID: PMC7139851 - DOI: 10.1158/1078-0432.CCR-19-1739
The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.
Nat Rev Cancer. 2020;20(1):26-41 - PMID: 31601988 - PMCID: PMC8246629 - DOI: 10.1038/s41568-019-0205-x
Mechanosensing tensile solid stresses.
Proc Natl Acad Sci U S A. 2019;116(44):21960-21962 - PMID: 31619566 - PMCID: PMC6825278 - DOI: 10.1073/pnas.1916115116
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
J Clin Oncol. 2019;37(35):3446-3454 - PMID: 31626572 - PMCID: PMC7098833 - DOI: 10.1200/JCO.19.01367
Vessel co-option in glioblastoma: emerging insights and opportunities.
Angiogenesis. 2020;23(1):9-16 - PMID: 31679081 - PMCID: PMC7012982 - DOI: 10.1007/s10456-019-09691-z
A Novel Approach to Quantifying Lymphatic Contractility during Indocyanine Green Lymphangiography.
Plast Reconstr Surg. 2019;144(5):1197-1201 - PMID: 31688768 - DOI: 10.1097/PRS.0000000000006176
Editorial: Regulation of Immune Function by the Lymphatic Vasculature.
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.
Sci Transl Med. 2019;11(523):ePub - PMID: 31852795 - PMCID: PMC7024563 - DOI: 10.1126/scitranslmed.aaw1565
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Proc Natl Acad Sci U S A. 2020;117(2):1129-1138 - PMID: 31879345 - PMCID: PMC6969504 - DOI: 10.1073/pnas.1910856117
A framework for advancing our understanding of cancer-associated fibroblasts.
Nat Rev Cancer. 2020;20(3):174-186 - PMID: 31980749 - PMCID: PMC7046529 - DOI: 10.1038/s41568-019-0238-1
Combining microenvironment normalization strategies to improve cancer immunotherapy.
Proc Natl Acad Sci U S A. 2020;117(7):3728-3737 - PMID: 32015113 - PMCID: PMC7035612 - DOI: 10.1073/pnas.1919764117
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
EBioMedicine. 2020;52:102644 - PMID: 32014823 - PMCID: PMC6997488 - DOI: 10.1016/j.ebiom.2020.102644
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Nat Rev Clin Oncol. 2020;17(4):251-266 - PMID: 32034288 - PMCID: PMC8272676 - DOI: 10.1038/s41571-019-0308-z
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Nat Biotechnol. 2020;38(4):420-425 - PMID: 32042168 - PMCID: PMC7456461 - DOI: 10.1038/s41587-019-0404-8
A multi-scale model for determining the effects of pathophysiology and metabolic disorders on tumor growth.
Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
1144